Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Clinical Trial Progress: Passage Bio has enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing on track and data from both cohorts expected in the first half of 2025. Interim results show PBFT02 is well-tolerated and effectively raises CSF progranulin levels.
Financial Overview: The company reported a net loss of $19.3 million for Q3 2024, down from $27.1 million in Q3 2023, with cash reserves expected to fund operations until the end of Q2 2026, indicating a strong financial position to support ongoing research and development efforts.
Trade with 70% Backtested Accuracy
Analyst Views on PASG
About PASG
About the author
Top Analysts Recommend 3 Biotech Stocks to Purchase Now, 11/12/2025
Top Biotech Stocks: Recent analyst updates highlight three biotech companies—Passage Bio, BioNTech, and Upstream Bio—that have received Strong Buy ratings from top Wall Street analysts, indicating solid upside potential.
Passage Bio (PASG): This clinical-stage biotech focuses on gene therapies for rare brain diseases, with a maintained Buy rating and a price target of $21, suggesting a potential upside of about 400%.
BioNTech (BNTX): Known for its mRNA technology in immunotherapies and vaccines, BioNTech has a Buy rating with a price target of $151, indicating a potential upside of approximately 29.37%.
Upstream Bio, Inc. (UPB): This company develops therapies for respiratory and inflammatory diseases, holding a Buy rating with a price target suggesting a potential upside of about 215.4%.
PASSAGE BIO, INC. Reports Reduced Q3 Loss, Surpassing Expectations
Earnings Report: PASSAGE BIO, INC. reported a loss of $7.75 million for the third quarter, a significant improvement from a loss of $19.34 million in the same period last year.
Earnings Per Share: The company's earnings per share (EPS) was -$2.44, compared to -$6.15 in the previous year, indicating a positive trend.
Analyst Expectations: The reported loss was better than analysts' expectations, who had predicted an EPS of -$2.97.
General Information: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Passage Bio Announces Financial Results for Q3 2025 and Shares Recent Business Updates
Clinical Trial Enrollment: Passage Bio is actively enrolling patients in Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) for its upliFT-D clinical trial, which aims to evaluate the safety and efficacy of PBFT02 in treating frontotemporal dementia.
FDA Alignment: The company has successfully aligned with the FDA on an analytical plan to establish comparability for its high-productivity PBFT02 manufacturing process, which is expected to enhance productivity and purity.
Regulatory Feedback Timeline: Passage Bio is on track to receive regulatory feedback on the trial design for FTD-GRN in the first half of 2026, with plans to report interim safety and biomarker data from Dose 2 around the same time.
Financial Overview: As of September 30, 2025, Passage Bio reported a cash position of $52.8 million, which is expected to fund operations into the first quarter of 2027, alongside a reduced net loss compared to the previous year.
Wall Street Analysts Predict Passage Bio (PASG) Could Soar by 731%: Important Insights Before You Invest
Passage Bio, Inc. Stock Performance
- Recent Trading Activity: Passage Bio, Inc. (PASG) closed at $7.13, reflecting a significant gain of 24.2% over the past four weeks.
- Analyst Price Targets: The mean price target for PASG is $59.25, suggesting a remarkable upside potential of 731%. Price targets range from a low of $10.00 to a high of $120.00, with a standard deviation of $46.71, indicating variability in analyst estimates.
Analyst Insights and Market Sentiment
- Earnings Estimate Revisions: Analysts show strong agreement in revising earnings estimates upward, with a 30.3% increase in the Zacks Consensus Estimate for the current year. This trend is often correlated with positive stock price movements.
- Skepticism Towards Price Targets: Despite the potential upside indicated by price targets, analysts caution that these figures can be misleading. Historical data suggests that price targets often do not accurately predict stock movements.
Investment Considerations
- Zacks Rank: PASG holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, which supports the stock's potential for growth.
- Caution for Investors: Investors are advised to approach price targets with skepticism and not rely solely on them for investment decisions, as they can lead to disappointing returns.
Future Opportunities
- Emerging Stock Picks: Zacks Investment Research has identified five stocks with high potential for significant gains, including a satellite-based communications firm projected to thrive in the growing trillion-dollar space industry. This firm is expected to see major revenue growth by 2025.
Guggenheim Maintains Buy on Passage Bio, Lowers Price Target to $10
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Upcoming Stock Splits This Week (July 14 to July 18) – Stay Invested
Upcoming Stock Splits: Several companies, including Beyond Air, Fusion Fuel Green, Lazydays Holdings, NextCure, and Passage Bio, are implementing reverse stock splits between July 14 and July 18 to raise their share prices and comply with Nasdaq's minimum bid price requirements.
Purpose of Stock Splits: Stock splits, whether traditional or reverse, aim to make shares more affordable for investors or help companies maintain compliance with exchange listing standards, signaling important market movements.
Top Analysts Recommend 3 Biotech Stocks to Purchase Now, 11/12/2025
Top Biotech Stocks: Recent analyst updates highlight three biotech companies—Passage Bio, BioNTech, and Upstream Bio—that have received Strong Buy ratings from top Wall Street analysts, indicating solid upside potential.
Passage Bio (PASG): This clinical-stage biotech focuses on gene therapies for rare brain diseases, with a maintained Buy rating and a price target of $21, suggesting a potential upside of about 400%.
BioNTech (BNTX): Known for its mRNA technology in immunotherapies and vaccines, BioNTech has a Buy rating with a price target of $151, indicating a potential upside of approximately 29.37%.
Upstream Bio, Inc. (UPB): This company develops therapies for respiratory and inflammatory diseases, holding a Buy rating with a price target suggesting a potential upside of about 215.4%.
PASSAGE BIO, INC. Reports Reduced Q3 Loss, Surpassing Expectations
Earnings Report: PASSAGE BIO, INC. reported a loss of $7.75 million for the third quarter, a significant improvement from a loss of $19.34 million in the same period last year.
Earnings Per Share: The company's earnings per share (EPS) was -$2.44, compared to -$6.15 in the previous year, indicating a positive trend.
Analyst Expectations: The reported loss was better than analysts' expectations, who had predicted an EPS of -$2.97.
General Information: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Passage Bio Announces Financial Results for Q3 2025 and Shares Recent Business Updates
Clinical Trial Enrollment: Passage Bio is actively enrolling patients in Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) for its upliFT-D clinical trial, which aims to evaluate the safety and efficacy of PBFT02 in treating frontotemporal dementia.
FDA Alignment: The company has successfully aligned with the FDA on an analytical plan to establish comparability for its high-productivity PBFT02 manufacturing process, which is expected to enhance productivity and purity.
Regulatory Feedback Timeline: Passage Bio is on track to receive regulatory feedback on the trial design for FTD-GRN in the first half of 2026, with plans to report interim safety and biomarker data from Dose 2 around the same time.
Financial Overview: As of September 30, 2025, Passage Bio reported a cash position of $52.8 million, which is expected to fund operations into the first quarter of 2027, alongside a reduced net loss compared to the previous year.
Wall Street Analysts Predict Passage Bio (PASG) Could Soar by 731%: Important Insights Before You Invest
Passage Bio, Inc. Stock Performance
- Recent Trading Activity: Passage Bio, Inc. (PASG) closed at $7.13, reflecting a significant gain of 24.2% over the past four weeks.
- Analyst Price Targets: The mean price target for PASG is $59.25, suggesting a remarkable upside potential of 731%. Price targets range from a low of $10.00 to a high of $120.00, with a standard deviation of $46.71, indicating variability in analyst estimates.
Analyst Insights and Market Sentiment
- Earnings Estimate Revisions: Analysts show strong agreement in revising earnings estimates upward, with a 30.3% increase in the Zacks Consensus Estimate for the current year. This trend is often correlated with positive stock price movements.
- Skepticism Towards Price Targets: Despite the potential upside indicated by price targets, analysts caution that these figures can be misleading. Historical data suggests that price targets often do not accurately predict stock movements.
Investment Considerations
- Zacks Rank: PASG holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, which supports the stock's potential for growth.
- Caution for Investors: Investors are advised to approach price targets with skepticism and not rely solely on them for investment decisions, as they can lead to disappointing returns.
Future Opportunities
- Emerging Stock Picks: Zacks Investment Research has identified five stocks with high potential for significant gains, including a satellite-based communications firm projected to thrive in the growing trillion-dollar space industry. This firm is expected to see major revenue growth by 2025.
Guggenheim Maintains Buy on Passage Bio, Lowers Price Target to $10
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Upcoming Stock Splits This Week (July 14 to July 18) – Stay Invested
Upcoming Stock Splits: Several companies, including Beyond Air, Fusion Fuel Green, Lazydays Holdings, NextCure, and Passage Bio, are implementing reverse stock splits between July 14 and July 18 to raise their share prices and comply with Nasdaq's minimum bid price requirements.
Purpose of Stock Splits: Stock splits, whether traditional or reverse, aim to make shares more affordable for investors or help companies maintain compliance with exchange listing standards, signaling important market movements.
